Loading
OT
Oncternal Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wills Robert James, was filed 10 Apr 2024.
Oncternal Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Oncternal Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at Oncternal Therapeutics, Inc. has published a filing in the past twelve months. The most recent one dates from 10 April 2024.
Since 2016, the database holds 43 purchases and 12 sales by insiders of the company.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
146
Thresholds
n/a
Buy Volume
€9M
43 ops. · all time
Sell Volume
€469,456
12 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$675.9k
Net income-US$34M-5029.2% margin
Last declaration on 10 April 2024
Declarations146 total
3,086 shares@ US$8.961329.0% of flowCommon StockSEC:0001209191-24-005283:0
Canonical exit: 7 Jul 2024 (T+90)
6,914 shares@ US$8.475961.7% of flowCommon StockSEC:0001209191-24-005154:0
Canonical exit: 26 Jun 2024 (T+90)
266 shares@ US$9.049.7% of flowCommon StockSEC:0001209191-24-004016:1
Canonical exit: 23 May 2024 (T+90)
980 shares@ US$9.049.3% of flowCommon StockSEC:0001209191-24-004015:0
714 shares@ US$9.0428.9% of flowCommon StockSEC:0001209191-24-004016:0
Canonical exit: 23 May 2024 (T+90)
4,485 shares@ US$0.49611.4% of flowCommon StockSEC:0001209191-24-000970:1
19,742 shares@ US$0.496121.6% of flowCommon StockSEC:0001209191-24-000973:0
8,868 shares@ US$0.496115.1% of flowCommon StockSEC:0001209191-24-000972:0
11,838 shares@ US$0.496113.9% of flowCommon StockSEC:0001209191-24-000971:0
50,955 shares@ US$0.496117.9% of flowCommon StockSEC:0001209191-24-000970:0
11,838 shares@ US$0.496136.0% of flowCommon StockSEC:0001209191-24-000974:0
4,007 shares@ US$0.360.9% of flowCommon StockSEC:0001209191-23-041319:1
10,305 shares@ US$0.368.8% of flowCommon StockSEC:0001209191-23-041318:0
47,992 shares@ US$0.3612.3% of flowCommon StockSEC:0001209191-23-041319:0
16,299 shares@ US$0.3613.0% of flowCommon StockSEC:0001209191-23-041314:0
10,897 shares@ US$0.3624.1% of flowCommon StockSEC:0001209191-23-041312:0
7,069 shares@ US$0.368.7% of flowCommon StockSEC:0001209191-23-041316:0
3,000 shares@ US$0.35976.6% of flowCommon StockSEC:0001209191-23-036994:1
Canonical exit: 12 Sept 2023 (T+90)
25,000 shares@ US$0.349857.6% of flowCommon StockSEC:0001209191-23-036994:0
Canonical exit: 10 Sept 2023 (T+90)
47,750 shares@ US$0.2998.8% of flowCommon StockSEC:0001209191-23-024390:1
Canonical exit: 13 Jul 2023 (T+90)
2,250 shares@ US$0.290.4% of flowCommon StockSEC:0001209191-23-024390:2
Canonical exit: 13 Jul 2023 (T+90)
100,000 shares@ US$0.2920.3% of flowCommon StockSEC:0001209191-23-024390:0
Canonical exit: 12 Jul 2023 (T+90)
10,000 shares@ US$0.295.4% of flowCommon StockSEC:0001209191-23-024264:1
Canonical exit: 12 Jul 2023 (T+90)
10,000 shares@ US$0.2855.7% of flowCommon StockSEC:0001209191-23-024371:1
Canonical exit: 12 Jul 2023 (T+90)
5,000 shares@ US$0.303.0% of flowCommon StockSEC:0001209191-23-024371:2
Canonical exit: 13 Jul 2023 (T+90)
25 of 146 declarations
About Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. (ticker: ONCT) is a U.S.-listed clinical-stage biotechnology company that traded on the NASDAQ market. For French-speaking investors, it fits the profile of a high-risk, event-driven micro-cap in healthcare, where valuation is driven primarily by clinical milestones, corporate actions, asset sales, and financing decisions rather than by recurring commercial revenue. The company was historically based in San Diego, California, United States, but its current website states that Oncternal is no longer operating in a normal business sense and provides a mailing address in Foxboro, Massachusetts for correspondence. ([oncternal.com](https://www.oncternal.com/?utm_source=openai))
Founded in 2013, Oncternal built its story around oncology and immuno-oncology drug development, targeting difficult-to-treat cancers and other serious diseases. Its lead asset has been OT-101, a TGF-beta inhibitor studied in oncology settings and, more recently, in viral respiratory disease-related applications. The company also advanced ONCT-534, an androgen receptor pathway program, alongside other research initiatives. This makes Oncternal a classic specialty biotech: a small company with a scientific pipeline rather than a mature product franchise, and with value creation tied to data generation, regulatory progress, and potential transaction opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1260990/000095017023022709/2023_ars.pdf?utm_source=openai))
Read moreShow less
In competitive terms, the company operated in one of the most crowded and capital-intensive areas of the life sciences industry. Its position was not that of a large commercial oncology player, but rather that of a niche developer trying to establish differentiated proof-of-concept in areas where efficacy and safety data are critical. That means its competitive strength depended on intellectual property, trial design, and strategic execution, while its weakness was the usual biotech burden of funding needs, binary clinical risk, and limited operating scale. ([oncternal.com](https://www.oncternal.com/?utm_source=openai))
Recent corporate developments materially changed the investment case. On July 1, 2025, Oncternal announced the sale of select development programs, indicating a portfolio simplification and possible monetization of non-core assets. Earlier, in March 2025, the company disclosed its intention to voluntarily delist from NASDAQ and deregister with the SEC, a major step that typically reduces liquidity and public-market visibility. The company’s own website now emphasizes that it is no longer operating, underscoring that the story is no longer one of normal operating momentum but rather of restructuring and wind-down style corporate events. ([oncternal.com](https://www.oncternal.com/ONCT-Press-Release-1-July.pdf?utm_source=openai))
For investors, Oncternal Therapeutics should be viewed as a special-situation former oncology biotech, historically listed on NASDAQ in the United States, with the key questions centered on residual asset value, transaction outcomes, and any remaining SEC/corporate event disclosures rather than on traditional growth metrics. ([oncternal.com](https://www.oncternal.com/?utm_source=openai))
